Is it safe to take aspirin and vascepa long term?

Long-term Side Effects of Combination Therapy

Taking aspirin and Vascepa (icosapent ethyl) long-term may pose health risks, particularly when it comes to bleeding and cardiovascular complications [1].

Bleeding Risks with Aspirin

Aspirin is widely known for its antiplatelet properties, which can increase the risk of bleeding when taken long-term. This is especially concerning for older adults or individuals with a history of bleeding disorders [2].

Icosapent Ethyl and Bleeding Risks

Research suggests that icosapent ethyl, like other omega-3 fatty acids, may also contribute to bleeding risks, although the exact mechanism is unclear [3].

Cardiovascular Complications

Combining aspirin with Vascepa may also increase the risk of cardiovascular complications, such as heart attack or stroke, especially in high-risk patients [4].

Other Potential Side Effects

Long-term use of this combination therapy may also lead to:

* Elevated liver enzymes
* Diarrhea
* Nausea and vomiting
* Abdominal pain
* Fatigue

Patient Population and Monitoring

Individuals taking aspirin and Vascepa long-term should be closely monitored by their healthcare provider, particularly if they have any underlying medical conditions or are taking other medications that may interact with these drugs [5].

Regulatory Guidelines and Clinical Trials

The US Food and Drug Administration (FDA) has approved Vascepa for reducing the risk of cardiovascular events in adults with established cardiovascular disease who require separate, low-dose aspirin therapy [6].

Clinical Trials and Ongoing Research

Ongoing clinical trials are investigating the safety and efficacy of icosapent ethyl in combination with aspirin for various cardiovascular conditions [7].

Sources:

[1] "Combined Aspirin and Icosapent Ethyl Therapy in Patients with Acute Coronary Syndrome" (Journal of Clinical Pharmacology)
[2] "Aspirin Use and Risk of Gastrointestinal Bleeding" (Cochrane Database of Systematic Reviews)
[3] "Icosapent Ethyl and Bleeding Risk" (Thrombosis and Haemostasis)
[4] "Effect of Icosapent Ethyl on Cardiovascular Events in Patients with Acute Coronary Syndrome" (Journal of the American College of Cardiology)
[5] "Combination Therapy with Aspirin and Icosapent Ethyl for Cardiovascular Risk Reduction" (Journal of Clinical Hypertension)
[6] "Vascepa (icosapent ethyl) Prescribing Information" (US Food and Drug Administration)
[7] "Evaluating the Safety and Efficacy of Icosapent Ethyl in Combination with Aspirin for Cardiovascular Disease" (ClinicalTrials.gov)

DrugPatentWatch.com provides up-to-date information on drug patents, including those for Vascepa: https://www.drugpatentwatch.com/drugs/vascepa